HRP20060147B1 - Terapijski sustav s kontroliranim otpuštanjem za nazalnu primjenu - Google Patents

Terapijski sustav s kontroliranim otpuštanjem za nazalnu primjenu

Info

Publication number
HRP20060147B1
HRP20060147B1 HRP20060147AA HRP20060147A HRP20060147B1 HR P20060147 B1 HRP20060147 B1 HR P20060147B1 HR P20060147A A HRP20060147A A HR P20060147AA HR P20060147 A HRP20060147 A HR P20060147A HR P20060147 B1 HRP20060147 B1 HR P20060147B1
Authority
HR
Croatia
Prior art keywords
controlled release
delivery system
release delivery
nasal applications
formulation
Prior art date
Application number
HRP20060147AA
Other languages
English (en)
Inventor
Claudia Mattern
Original Assignee
M & P Patent Aktiengesellschaft, C/O Fundationanstalt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by M & P Patent Aktiengesellschaft, C/O Fundationanstalt filed Critical M & P Patent Aktiengesellschaft, C/O Fundationanstalt
Publication of HRP20060147A2 publication Critical patent/HRP20060147A2/xx
Publication of HRP20060147B1 publication Critical patent/HRP20060147B1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

Ovaj izum odnosi se na pernazalno primjenjiv pripravak za kontrolirano otpuštanje spolnih hormona u sistemski krvotok, naročito pripravak koji aktivnim sastojcima omogućava apsorbiranje na kontinuirani način, omogućavajući tako bolju biodostupnost pri vrlo niskim dozama, te dulje djelovanje.
HRP20060147AA 2003-11-11 2006-04-18 Terapijski sustav s kontroliranim otpuštanjem za nazalnu primjenu HRP20060147B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03025769A EP1530965B1 (en) 2003-11-11 2003-11-11 Controlled release delivery system of sexual hormones for nasal application
PCT/EP2004/012122 WO2005044273A1 (en) 2003-11-11 2004-10-27 Controlled release delivery system for nasal applications

Publications (2)

Publication Number Publication Date
HRP20060147A2 HRP20060147A2 (en) 2006-11-30
HRP20060147B1 true HRP20060147B1 (hr) 2014-02-14

Family

ID=34429314

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20060147AA HRP20060147B1 (hr) 2003-11-11 2006-04-18 Terapijski sustav s kontroliranim otpuštanjem za nazalnu primjenu

Country Status (23)

Country Link
US (6) US20050100564A1 (hr)
EP (1) EP1530965B1 (hr)
JP (1) JP4616270B2 (hr)
KR (1) KR100861443B1 (hr)
AR (1) AR047722A1 (hr)
AT (1) ATE319426T1 (hr)
AU (1) AU2004286781B2 (hr)
BR (1) BRPI0416370B8 (hr)
CA (1) CA2541498C (hr)
DE (1) DE60303854T2 (hr)
DK (1) DK1530965T3 (hr)
ES (1) ES2258694T3 (hr)
HR (1) HRP20060147B1 (hr)
MY (1) MY131483A (hr)
NO (1) NO338665B1 (hr)
PL (1) PL219338B1 (hr)
PT (1) PT1530965E (hr)
RU (1) RU2331423C2 (hr)
SA (1) SA04250363B1 (hr)
SI (1) SI1530965T1 (hr)
TW (1) TWI350176B (hr)
WO (1) WO2005044273A1 (hr)
ZA (1) ZA200603115B (hr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399176B1 (en) 1996-10-01 2002-06-04 Magotteaux International S.A. Composite wear component
JP4222944B2 (ja) 2001-12-04 2009-02-12 マゴット アンテルナショナル エス．アー． 強化された摩耗抵抗性を持つ鋳造部品
US8784869B2 (en) 2003-11-11 2014-07-22 Mattern Pharma Ag Controlled release delivery system for nasal applications and methods of treatment
EP1530965B1 (en) 2003-11-11 2006-03-08 Mattern, Udo Controlled release delivery system of sexual hormones for nasal application
KR101292492B1 (ko) 2004-05-11 2013-08-01 이모셔널 브레인 비.브이. 약제학적 제형물 및 여성 성기능 부전의 치료에서 그것의용도
US20060140820A1 (en) 2004-12-28 2006-06-29 Udo Mattern Use of a container of an inorganic additive containing plastic material
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
CN101600417B (zh) * 2006-10-04 2012-05-30 M&P专利股份公司 用于神经递质的经鼻施用的控制释放递送系统
US8147980B2 (en) 2006-11-01 2012-04-03 Aia Engineering, Ltd. Wear-resistant metal matrix ceramic composite parts and methods of manufacturing thereof
EP1925307A1 (en) 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
DE102010023949A1 (de) * 2010-06-16 2011-12-22 F. Holzer Gmbh In-situ Lecithin-Mikroemulsionsgel-Formulierung
GB2482868A (en) 2010-08-16 2012-02-22 Franciscus Wilhelmus Henricus Maria Merkus A testosterone liquid spray formulation for oromucosal administration
US20130040922A1 (en) * 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal 0.45% and 0.48% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
AR086400A1 (es) 2011-05-13 2013-12-11 Trimel Pharmaceuticals Corp Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
KR20140033407A (ko) * 2011-05-13 2014-03-18 트리멜 바이오파마 에스알엘 비강내 저 용량 강도 테스토스테론 겔 제형 및 성불감증 또는 성욕 감퇴 장애를 치료하기 위한 이의 용도
US20130045958A1 (en) * 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
EP2709588B1 (en) * 2011-05-15 2021-08-25 Acerus Biopharma Inc. Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration
EA202192397A3 (ru) * 2011-05-16 2022-03-31 Эйсерус Биофарма Инк. Интраназальные биоадгезивные тестостероновые составы в виде гелей и их применение для лечения мужского гипогонадизма
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
PT2782584T (pt) 2011-11-23 2021-09-02 Therapeuticsmd Inc Preparações e terapias de substituição para hormonoterapias naturais combinadas
CN108841802B (zh) 2012-05-11 2023-06-09 珍白斯凯尔有限公司 抗炎性肽及包含其的组合物
JP6262721B2 (ja) 2012-05-11 2018-01-17 ジェムバックス アンド カエル カンパニー，リミティド 敗血症の予防用または治療用の組成物
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
WO2014010971A1 (ko) 2012-07-11 2014-01-16 주식회사 카엘젬백스 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
WO2014083432A2 (en) * 2012-11-14 2014-06-05 Trimel Biopharma Srl Female intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
WO2014076569A2 (en) * 2012-11-14 2014-05-22 Trimel Biopharma Srl Controlled release topical testosterone formulations and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
KR102258864B1 (ko) 2013-04-19 2021-06-01 주식회사 젬백스앤카엘 허혈성 손상 치료 및 예방용 조성물
WO2014196841A1 (en) 2013-06-07 2014-12-11 Kael-Gemvax Co., Ltd. Biological markers useful in cancer immunotherapy
CN105324123B (zh) 2013-06-21 2022-02-08 珍白斯凯尔有限公司 激素分泌调节剂、包含该调节剂的组合物、和利用其控制激素分泌的方法
JP6382972B2 (ja) 2013-10-23 2018-08-29 ジェムバックス アンド カエル カンパニー，リミティド 前立腺肥大治療用及びその予防用の組成物
JP6553605B2 (ja) 2013-11-22 2019-07-31 ジェムバックス アンド カエル カンパニー，リミティド 血管新生抑制活性を有するペプチド、及びそれを含む組成物
ES2809251T3 (es) 2013-12-17 2021-03-03 Gemvax & Kael Co Ltd Composición para tratar cáncer de próstata
EP3130345B9 (en) 2014-04-11 2022-05-04 Gemvax & Kael Co., Ltd. Peptide having fibrosis inhibitory activity and composition containing same
KR102232320B1 (ko) 2014-04-30 2021-03-26 주식회사 젬백스앤카엘 장기, 조직 또는 세포 이식용 조성물, 키트 및 이식 방법
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
CA2951284A1 (en) 2014-07-29 2016-02-04 Therapeuticsmd, Inc. Transdermal cream
ES2877107T3 (es) 2014-08-28 2021-11-16 Univ Texas Formulaciones de testosterona y procedimientos de tratamiento con ellas
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
US10835582B2 (en) 2015-02-27 2020-11-17 Gemvax & Kael Co. Ltd. Peptide for preventing hearing loss, and composition comprising same
EP3318265B1 (en) 2015-07-02 2021-08-18 Gemvax & Kael Co., Ltd. Peptide having anti-viral effect and composition containing same
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
BR102015020878B1 (pt) * 2015-08-28 2019-08-27 F B M Ind Farmaceutica Ltda formulação farmacêutica nasal de testosterona e “kit” em forma de cartela de dispositivos nasais unitários para aplicação de monodose de testosterona.
CA3016542A1 (en) * 2016-03-02 2017-09-08 Board Of Regents, The University Of Texas System Formulations of testosterone and methods of treatment therewith
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
CN109328068A (zh) 2016-04-07 2019-02-12 珍白斯凯尔有限公司 具有增加端粒酶活性和延长端粒的效果的肽以及包含该肽的组合物
MX2018014906A (es) 2016-06-03 2019-08-21 M et P Pharma AG Composiciones farmaceuticas nasales con un excipiente poroso.
HUE063346T2 (hu) 2017-01-20 2024-01-28 M et P Pharma AG Nazális gyógyszerészeti készítmények légszennyezõ anyagoknak való kitettség kockázatainak csökkentésére
LT3698791T (lt) 2017-02-02 2024-02-12 Otolanum Ag Intranazalinė kompozicija, apimanti betahistiną
US11234928B2 (en) 2017-11-27 2022-02-01 Aska Pharmaceutical Co., Ltd. Powder preparation for nasal administration
CA3087840A1 (en) 2018-01-11 2019-07-18 M et P Pharma AG Treatment of demyelinating diseases
CA3066284A1 (en) 2018-04-09 2019-10-17 Katana Pharmaceuticals, Inc. Oxytocin compositions and methods of use
CA3097090A1 (en) 2018-04-17 2019-10-24 M et P Pharma AG Compositions and methods for intranasal delivery of pregnenolone
WO2020084548A1 (en) * 2018-10-26 2020-04-30 Viramal Limited Mucoadhesive gel composition
CN113365635A (zh) * 2018-12-14 2021-09-07 阿克罗斯生物制药公司 睾酮的活性酯衍生物、组合物和其用途
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4315925A (en) * 1980-05-30 1982-02-16 University Of Kentucky Research Foundation Method of administering natural female sex hormones
US4581225A (en) * 1984-04-25 1986-04-08 Eli Lilly And Company Sustained release intranasal formulation and method of use thereof
EP0349091A1 (en) * 1988-07-01 1990-01-03 Walter Adrianus Josephus Johannes Hermens Pharmaceutical composition
US5863554A (en) * 1987-05-22 1999-01-26 Danbiosyst Uk Limited Enhanced uptake drug delivery system
US6432440B1 (en) * 1997-04-18 2002-08-13 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Pectin compositions and methods of use for improved delivery of drugs to mucosal surfaces

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE943792C (de) * 1949-02-18 1956-06-01 Organon Nv Verfahren zur Herstellung von injizierbaren Hormonpraeparaten
GB1032874A (en) 1964-02-13 1966-06-15 Du Pont Stabilized polyoxymethylenes
NL7506407A (nl) * 1975-05-30 1976-12-02 Akzo Nv Werkwijze ter bereiding van een oraal werkzaam far- maceutisch preparaat.
NL7510104A (nl) * 1975-08-27 1977-03-01 Akzo Nv Werkwijze ter bereiding van een oraal werkzaam farmaceutisch preparaat.
DE2548413A1 (de) * 1975-10-27 1977-04-28 Schering Ag Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion
US4752425A (en) * 1986-09-18 1988-06-21 Liposome Technology, Inc. High-encapsulation liposome processing method
US5049387A (en) * 1987-03-09 1991-09-17 Alza Corporation Inducing skin tolerance to a sensitizing drug
JP2543708B2 (ja) * 1987-07-13 1996-10-16 旭化成工業株式会社 難溶性薬物を封入したエマルジョン製剤の製造方法
GB2237510B (en) 1989-11-04 1993-09-15 Danbiosyst Uk Small particle drug compositions for nasal administration
US5397771A (en) * 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
US5221698A (en) 1991-06-27 1993-06-22 The Regents Of The University Of Michigan Bioactive composition
US5756071A (en) * 1992-06-03 1998-05-26 Arrowdean Limited Method for nasally administering aerosols of therapeutic agents to enhance penetration of the blood brain barrier
SE9301171D0 (sv) * 1993-04-07 1993-04-07 Ab Astra Pharmaceutical composition containing lipophilic drugs
NZ279954A (en) 1994-02-04 1998-02-26 Scotia Lipidteknik Ab Lipophilic carrier preparation comprising a galacto-lipid material at least 50% of which comprises digalactosyldiacylglycerols
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5635203A (en) 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
US6624200B2 (en) 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US5877216A (en) * 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
US5897894A (en) * 1997-12-29 1999-04-27 General Mills, Inc. Microwave popcorn with coarse salt crystals and method of preparation
GB9823246D0 (en) * 1998-10-24 1998-12-16 Danbiosyst Uk A nasal drug delivery composition
GB9828861D0 (en) 1998-12-31 1999-02-17 Danbiosyst Uk Compositions
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
IL145524A0 (en) * 1999-04-01 2002-06-30 Akzo Nobel Nv Formulation comprising testosterone undecanoate and castor oil
US6287588B1 (en) 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
JP5184727B2 (ja) 1999-06-11 2013-04-17 ワトソン ファーマシューティカルズ， インコーポレイテッド 女性への非経口アンドロゲンステロイドの投与
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
DE60020382T2 (de) 1999-09-21 2006-01-26 Skyepharma Canada Inc., Verdun Oberflächenmodifizierte teilchenförmige zusammensetzungen biologisch aktiver stoffe
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
AU1261501A (en) 1999-12-06 2001-06-18 Stanley L. Gore Compositions and methods for intranasal delivery of active agents to the brain
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20030139384A1 (en) 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
US20040092494A9 (en) 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20020072509A1 (en) 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
US6730330B2 (en) * 2001-02-14 2004-05-04 Gw Pharma Limited Pharmaceutical formulations
KR20040052489A (ko) * 2001-03-06 2004-06-23 셀러지 파마세우티칼스, 인크 비뇨생식기 장애 치료용 화합물 및 그 방법
US6833478B2 (en) 2001-07-13 2004-12-21 Sri International N,N-dinitramide salts as solubilizing agents for biologically active agents
JP2005523262A (ja) * 2002-02-01 2005-08-04 ファイザー・プロダクツ・インク 薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物
EA007431B1 (ru) 2002-03-15 2006-10-27 Юнимед Фармасьютикалз, Инк. Андрогенная фармацевтическая композиция и способ для лечения депрессии
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
US6958142B2 (en) 2002-08-02 2005-10-25 Balance Pharmaceuticals, Inc. Nasal spray formulation and method
US7029657B2 (en) 2002-08-02 2006-04-18 Balance Pharmaceuticals, Inc. Nasal spray steroid formulation and method
US20040259852A1 (en) 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
US8784869B2 (en) 2003-11-11 2014-07-22 Mattern Pharma Ag Controlled release delivery system for nasal applications and methods of treatment
EP1530965B1 (en) * 2003-11-11 2006-03-08 Mattern, Udo Controlled release delivery system of sexual hormones for nasal application
WO2005065185A2 (en) 2003-12-24 2005-07-21 Collegium Pharmaceuticals, Inc. Temperature-stable formulations, and methods of development thereof
US20060140820A1 (en) 2004-12-28 2006-06-29 Udo Mattern Use of a container of an inorganic additive containing plastic material
CN101600417B (zh) 2006-10-04 2012-05-30 M&P专利股份公司 用于神经递质的经鼻施用的控制释放递送系统

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4315925A (en) * 1980-05-30 1982-02-16 University Of Kentucky Research Foundation Method of administering natural female sex hormones
US4581225A (en) * 1984-04-25 1986-04-08 Eli Lilly And Company Sustained release intranasal formulation and method of use thereof
US5863554A (en) * 1987-05-22 1999-01-26 Danbiosyst Uk Limited Enhanced uptake drug delivery system
EP0349091A1 (en) * 1988-07-01 1990-01-03 Walter Adrianus Josephus Johannes Hermens Pharmaceutical composition
US6432440B1 (en) * 1997-04-18 2002-08-13 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Pectin compositions and methods of use for improved delivery of drugs to mucosal surfaces

Also Published As

Publication number Publication date
US8877230B2 (en) 2014-11-04
NO20062619L (no) 2006-06-07
US8784882B2 (en) 2014-07-22
BRPI0416370B8 (pt) 2021-05-25
DE60303854T2 (de) 2006-08-10
DK1530965T3 (da) 2006-07-17
WO2005044273A1 (en) 2005-05-19
TW200515918A (en) 2005-05-16
KR100861443B1 (ko) 2008-10-02
US20120009250A1 (en) 2012-01-12
PL219338B1 (pl) 2015-04-30
ZA200603115B (en) 2007-09-26
BRPI0416370A (pt) 2007-05-22
PL379867A1 (pl) 2006-11-27
JP2007530446A (ja) 2007-11-01
CA2541498C (en) 2009-05-26
CA2541498A1 (en) 2005-05-19
MY131483A (en) 2007-08-30
AU2004286781B2 (en) 2010-06-03
KR20060109903A (ko) 2006-10-23
RU2331423C2 (ru) 2008-08-20
ES2258694T3 (es) 2006-09-01
JP4616270B2 (ja) 2011-01-19
US20120083480A1 (en) 2012-04-05
US20070149454A1 (en) 2007-06-28
BRPI0416370B1 (pt) 2018-09-18
ATE319426T1 (de) 2006-03-15
EP1530965B1 (en) 2006-03-08
NO338665B1 (no) 2016-09-26
PT1530965E (pt) 2006-05-31
HRP20060147A2 (en) 2006-11-30
SA04250363B1 (ar) 2013-03-13
SI1530965T1 (sl) 2006-06-30
US20100311707A1 (en) 2010-12-09
AU2004286781A1 (en) 2005-05-19
DE60303854D1 (de) 2006-05-04
TWI350176B (en) 2011-10-11
US20050100564A1 (en) 2005-05-12
RU2006120468A (ru) 2007-12-27
EP1530965A1 (en) 2005-05-18
US8574622B2 (en) 2013-11-05
WO2005044273A8 (en) 2006-08-31
AR047722A1 (es) 2006-02-15
US20120058176A1 (en) 2012-03-08

Similar Documents

Publication Publication Date Title
HRP20060147B1 (hr) Terapijski sustav s kontroliranim otpuštanjem za nazalnu primjenu
AR059350A1 (es) Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
ATE471144T1 (de) Intranasale verabreichung von schnell wirkendem insulin
ECSP10010224A (es) Formulaciones líquidas de hormona luteinizante (lh).
DE122011100049I1 (de) Stabile pharmazeutische Losungsformulierungen fur unter Druck stehende Inhaliergerate fur die Verabreichung abgemessener Dosen.
ECSP088403A (es) Formulacion farmaceutica de absorción oral y su método de administracion
EA200800360A1 (ru) Формуляции с высоким содержанием лекарства и дозированные формы
WO2005016423A3 (en) Delivery devices
TN2011000229A1 (en) Antibody formulation
DK1389137T3 (da) Sammensætninger til lungelægemiddellevering af protein
AR064614A1 (es) Producto combinado par controlar parasitos en animales
WO2006135933A3 (en) Stable fixed-dose unitary formulations containing tenofovir, a surfactant, efavirenz and emtricitabine
RS52367B (en) GLATIRAMER ACETATE FORMULATION FORMATED VOLUMES AND APPLICATION PROCEDURES
DK2068825T3 (da) Kontrolleret frisætningstilførselssystem til nasal påføring af neurotransmittere
MXPA06011467A (es) Combinacion de sustancias activas que comprenden un carbinol combinado con al menos un farmaco antiinflamatorio no esteroideo (nsaid).
MX2009003030A (es) Forma galenita para la administracion por via transmucosa de principios activos.
MX2010004388A (es) Formulaciones de hormona paratiroidea y usos de las mismas.
ATE507818T1 (de) Orale verabreichung eines calcitonins
NO20023551D0 (no) Ibuprofen-inneholdende aktivt middel-preparat
BRPI0504082A (pt) emulsões refrescantes medicinais
MX2010008285A (es) Forma galenica para la administracion de triptanos por via trans-mucosa bucal.
HRP20070081T5 (hr) Nazalni farmaceutski pripravak piribedila
UY27857A1 (es) Medicamento para el tratamiento del "síndrome de respuesta inflamatoria sistémica"
CY1115072T1 (el) Συνθεσεις υγρου σπρει για χορηγηση κανναβινοειδων μεσω παρειας
TH1701001848A (th) อุปกรณ์สูดดม

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
PPPP Transfer of rights

Owner name: M & P PATENT AKTIENGESELLSCHAFT, C/O FUNDATIONANST

B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20191017

Year of fee payment: 16

ODRP Renewal fee for the maintenance of a patent

Payment date: 20201016

Year of fee payment: 17

ODRP Renewal fee for the maintenance of a patent

Payment date: 20211019

Year of fee payment: 18

PBON Lapse due to non-payment of renewal fee

Effective date: 20221027